undamentalytics Newsletter
Sign in

Immucell Corp cash flow statement

In fiscal 2025, Immucell Corp's operations generated $2.5m of cash; it spent $1.3m on capital projects, leaving free cash flow of $1.2m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−0−1−00103−01−0011−2−5026
Depreciation and amortisation000000111222223332
Stock-based pay000000000000000001
Capital spending0000123418214342012
Free cash flow−1−1−001−10−4−17−2−1−3−2−6−7−014
Free cash flow after stock pay−1−1−000−10−4−17−3−1−3−2−6−7−014
Shares issued———————————00——500

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: FAMI vs ICCCICCC vs WFCFICCC vs RYMICCC vs LOCL

More: Agricultural Products & Services stocks compared, Consumer Staples sector, rankings of US companies

Figures from Immucell Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Immucell Corp.